
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is a promising biopharmaceutical company with a strong focus on developing and commercializing their main therapeutic candidate, ONS-5010, for the treatment of wet age-related macular degeneration (wAMD). Despite facing some challenges with FDA approvals, the company has demonstrated promising clinical progress and a potential for significant revenue growth in the future. With multiple positive developments in their pipeline, there is a high possibility for a successful launch and significant upside potential for the company's stock.
Bears say
Outlook Therapeutics is facing multiple challenges in the near future, with the FDA issuing a third Complete Response Letter for their resubmitted BLA for ONS-5010. Additionally, while their current European launch of LYTENAVA has been successful, they face potential pricing and reimbursement obstacles in the U.S market. Furthermore, the use of compounded bevacizumab could decrease if LYTENAVA is approved, presenting a threat to OTLK's potential market share.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares